Aug. 25 at 4:31 PM
$ENSC $ENSC ACCUMULATING ! Analysts see massive upside.
Pivotal Phase 3 Study for PF614 Initiated: Announced August 2025, this late-stage trial for their lead abuse-deterrent opioid could lead to FDA approval, addressing a
$10B+ pain management market.
PF614-MPAR-102 Study Accelerated: Full enrollment in Part 2, building on positive FDA feedback for this breakthrough opioid with overdose protection.
Fast Track and Breakthrough Therapy designations highlight regulatory support for TAAP (abuse prevention) and MPAR (overdose protection) tech.
Q2 2025 Results: Narrowed net loss to
$2.1M from
$3.5M YoY, with cash runway extended to Q2 2026. Focus on clinical milestones without dilution.
Strong Buy ratings from firms like Zacks.
Market Opportunity
Opioid epidemic drives demand for safer alternatives; ENSC's tech reduces abuse/overdose risks, aligning with FDA priorities.
Low float (~3M shares) + catalysts = volatility, but upside potential is huge.
